Overlap syndromes among autoimmune liver diseases

Abstract

The three major immune disorders of the liver are autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). Variant forms of these diseases are generally called overlap syndromes, although there has been no standardized definition. Patients with overlap syndromes present with both hepatitic and cholestatic serum liver tests and have histological features of AIH and PBC or PSC. The AIH-PBC overlap syndrome is the most common form, affecting almost 10% of adults with AIH or PBC. Single cases of AIH and autoimmune cholangitis (AMA-negative PBC) overlap syndrome have also been reported. The AIH-PSC overlap syndrome is predominantly found in children, adolescents and young adults with AIH or PSC. Interestingly, transitions from one autoimmune to another have also been reported in a minority of patients, especially transitions from PBC to AIH-PBC overlap syndrome. Overlap syndromes show a progressive course towards liver cirrhosis and liver failure without treatment. Therapy for overlap syndromes is empiric, since controlled trials are not available in these rare disorders. Anticholestatic therapy with ursodeoxycholic acid is usually combined with immunosuppressive therapy with corticosteroids and/or azathioprine in both AIH-PBC and AIH-PSC overlap syndromes. In end-stage disease, liver transplantation is the treatment of choice.

Key words: Autoimmune hepatitis; Immunosuppressive agents; Primary biliary cirrhosis; Primary sclerosing cholangitis; Ursodeoxycholic acid
DIAGNOSIS OF AUTOIMMUNE LIVER DISEASES

The diagnostic criteria of AIH, PBC and PSC are discussed in detail in this issue of the World Journal of Gastroenterology and are therefore just summarized briefly, since they are the basis for the diagnosis of the respective overlap syndrome.

AIH

The diagnosis of AIH depends on several descriptive criteria which were summarized and updated by the International AIH Group (IAIHG) in 1999[11]. A definite diagnosis requires exclusion of other major causes of liver damage, including alcoholic, viral, drug- and toxin-induced, and hereditary liver disease. The scoring system includes characteristic laboratory features (hepatitic serum liver tests, the presence of elevated serum IgG or γ-globulins and of serum autoantibodies), histocompatibility leucocyte antigen (HLA) associations, a portal mononuclear cell infiltration and interface hepatitis in the liver tissue and a positive treatment response to corticosteroids[19].

PBC

The diagnosis of PBC is based on a cholestatic serum enzyme pattern, serum antimitochondrial antibodies (AMA) and/or PBC-specific AMA-M2, and a compatible histology. Although elevated serum IgM is characteristic for patients with PBC, it is not regarded mandatory to establish the diagnosis[12,13]. PBC is frequently associated with other autoimmune disorders, like Sjögren’s syndrome, Hashimoto thyroiditis, and celiac disease.

PSC

PSC is a rare chronic cholestatic disease of the liver and bile ducts that is generally progressive and leads to end-stage liver disease. In contrast to PBC, twice as many men as women are affected. PSC is diagnosed most frequently in patients aged between 25 and 40 years[14]. Criteria for the diagnosis of PSC include cholestatic serum enzyme pattern, typical cholangiographic findings of bile duct stenoses and dilatations and histologic findings compatible with PSC showing mild to moderate portal infiltration[14,15]. Concomitant inflammatory bowel disease is found in 70%-90% of the patients and atypical perinuclear antineutrophil cytoplasmatic antibodies (pANCA) are detected in more than 70% of the patients[16].

AIH-PBC OVERLAP SYNDROME

PBC and AIH are the most frequent autoimmune hepatopathies with a prevalence of 25-40/100000[17,24] and 17/100000[18], respectively, in recent epidemiologic studies in Europe and the United States and female gender predominates in both AIH (80%) and PBC (90%-95%). Serum liver tests typically show a hepatic pattern in AIH and a cholestatic pattern with marked elevation of aP and γ-GT, but mild elevation of serum transaminases in PBC. While serum IgG is the predominant immunoglobulin elevated in AIH, serum IgM is elevated in most patients with PBC.

Patients presenting with clinical, biochemical, serological and histological features of both diseases have been reported since the 1970s[20,21]. Later, the term “overlap syndrome” was used to describe these conditions, although there was no common definition or uniformly accepted diagnostic criteria for this[22,23]. Two extended analyses provided evidence for AIH-PBC overlap in 8% of 199 patients with AIH (n = 162) or PBC (n = 37)[1] and in 9% of 130 patients with PBC[5]. In the latter study, an AIH-PBC overlap syndrome was accepted when 2 or 3 criteria for PBC and AIH were fulfilled[5] (Table 1). Although these diagnostic criteria for an AIH-PBC overlap syndrome are not validated and their sensitivity has not been established, they provide a diagnostic template that can be consistently applied[4].

In a comparative study, patients with AIH-PBC overlap syndrome presented with typical features of PBC (AMA-M2 positive, bile duct damage compatible with PBC), but a more hepatic picture than a cohort of PBC patients[24]. Patients with AIH-PBC overlap syndrome showed a predominant HLA type B8, DR3, or DR4 similar to AIH and a good response to corticosteroid treatment, and this was, therefore, named “PBC, hepatic form”[24]. Autoantibodies are generally believed to present a hallmark for the diagnosis of AIH, but up to 20% of patients with AIH present without antinuclear antibodies (ANA), anti-smooth muscle antibodies (ASMA), or antibodies against liver-kidney-microsomes (LKM) 1[21]. ANA represent the least specific serum autoantibodies for the diagnosis of chronic liver diseases and are also found in 30% of elderly healthy controls, 10% of pregnant women, and 30% of patients with malignancies[25]. Serum ANA in patients with PBC are not a marker of AIH-PBC overlap syndrome, but often found in PBC patients without further signs of AIH[26]. In contrast, ANA with a specific immunofluorescence pattern of multiple nuclear dots directed against Sp100 (5-10 dots) or Collin p80 (2-6 dots) are rather specific although less sensitive for PBC[25]. In 3.9% of 233 patients with PBC, the presence of soluble liver antigen (SLA) autoantibodies was found to be a marker of AIH-PBC overlap syndrome with a good

Table 1 Diagnostic criteria of AIH-PBC overlap syndrome proposed by Chazouillères et al in 1998[11]

| Criteria                                      | Criteria                                      |
|-----------------------------------------------|-----------------------------------------------|
| AIH (2 out of 3 criteria)                     | PBC (2 out of 3 criteria)                     |
| (1) Alanine aminotransferase (ALT) levels > 5 × ULN | (1) Alkaline phosphatase (AP) levels > 2 × or γ-glutamyltranspeptidase (GGT) levels > 5 × ULN |
| (2) Serum immunoglobulin G (IgG) levels > 2 × ULN or a positive test for smooth muscle antibodies (ASMA) | (2) Positive test for antimitochondrial antibodies (AMA) |
| (3) liver biopsy showing moderate or severe perportal or periportal lymphocytic piecemeal necrosis | (3) Liver biopsy specimen showing florid bile duct lesions |

ULN: Upper limit of normal value.

www.wjgnet.com
response to immunosuppressive therapy\textsuperscript{27}.

In addition to AIH-PBC overlap syndrome, some patients presented with typical features of PBC or AIH\textsuperscript{[28]}. A well-defined series of 12 patients with PBC followed by AIH was described in 282 PBC patients\textsuperscript{[29]}. The time interval between the diagnosis of PBC and the diagnosis of AIH varied from 6 mo to 13 years. Of importance, patients with multiple flares of hepatitis at the time of diagnosis of AIH had already developed cirrhosis on liver biopsy\textsuperscript{[29]}. Remission was achieved in 80\% of the patients who received additional immunosuppressive therapy. This case series emphasizes the possible role of AIH in the deterioration of liver function in PBC patients unless diagnosis is made early and steroid therapy is administered. This study suggested that these patients may have two coincident autoimmune diseases rather than a variant of PBC or AIH\textsuperscript{[29]}. A recent retrospective analysis indicated that patients with AIH-PBC overlap syndrome might have worse clinical outcomes compared to patients with PBC alone\textsuperscript{[30,31]}. However, this conclusion is somewhat controversial, since the treatment was not standardized and no difference was found when the diagnostic criteria proposed by Chazouilleres et al\textsuperscript{[30]} were applied in this cohort of patients.

**Therapy**

Randomized controlled trials are the best method to address therapeutic issues. However, the low prevalence of AIH-PBC overlap syndrome has made controlled therapeutic trials in these patients impossible so far. Thus, therapeutic recommendations still rely on the experience in the treatment of either AIH or PBC, and on retrospective, non-randomized studies with inherent limitations. It remains controversial if patients with AIH-PBC overlap syndrome require immunosuppressive treatment in addition to ursodeoxycholic acid (UDCA). In a strictly defined cohort of 16 patients with AIH-PBC overlap syndrome, the response to UDCA therapy (13-15 mg/kg daily) and the survival of the patients were similar to patients with classical PBC\textsuperscript{[31]}. However, other groups reported that a combined therapy of UDCA and corticosteroids is required in most patients to obtain a complete biochemical response\textsuperscript{[3,24]}. This question was addressed again recently in a retrospective study of 17 patients with AIH-PBC overlap syndrome\textsuperscript{[32]}. In this study, patients received UDCA alone or UDCA in combination with immunosuppressants and were followed up for 7.5 years. In the patients treated with UDCA alone, biochemical response was observed in only 3 patients whereas 8 patients were non-responders and 50\% of them showed increased fibrosis. All but one of the non-responders subsequently received combined therapy, and 85\% of the patients achieved biochemical remission\textsuperscript{[33]}. In the second group of patients who received combined therapy throughout the study, fibrosis did not progress and 67\% achieved biochemical remission. Thus, it appears appropriate to start treatment with UDCA (13-15 mg/kg daily). However, if this therapy does not induce an adequate biochemical response in an appropriate time span (e.g. 3 mo) or in patients with predominantly hepatic serum liver tests, a glucocorticosteroid should be added. Prednisone has been used at an initial dose of 0.5 mg/kg daily and should be progressively tapered once ALT levels show a response\textsuperscript{[33]}. The role of other immuno-suppressants, e.g. azathioprine (1-1.5 mg/kg daily) in the long-term management of patients with AIH-PBC overlap syndrome is unclear, but its successful use in AIH makes azathioprine an attractive alternative to corticosteroids for long-term immunosuppressive therapy\textsuperscript{[33-35]}. Budesonide, a synthetic corticosteroid with a high first pass metabolism that reduces its systemic side effects, is a promising treatment option for patients with AIH and has also been used in patients with AIH-PBC overlap syndrome with success\textsuperscript{[31,34]}. For corticosteroid-resistant patients with AIH-PBC overlap syndrome, intermediate treatment with other immunosuppressants such as cyclosporine A has been considered\textsuperscript{[30]}. Liver transplantation is regarded as the treatment of choice for end-stage disease.

**A case report of AIH-PBC overlap syndrome**

A 57-year-old woman presented to our outpatient clinic in May 2007 for evaluation of abnormal serum liver tests. She reported fatigue and slight pruritus, but was otherwise in good general health. In January 2007, elevated serum liver tests were detected for the first time when she went for a routine medical examination. At presentation, serum liver tests revealed elevated \(γ\)-GT (2 × N), elevated transaminases (AST 2.5 × N, ALT 5.5 × N), and normal bilirubin. Serum AMA (1:3840) and AMA-M2, ASMA and SLA were positive, whereas ANA, LKM1 and ANCA were all negative. Her immunoglobulins showed elevated IgG (23.2 g/L) and IgM (3.3 g/L). Metabolic and viral liver diseases were ruled out. A liver biopsy disclosed an interface hepatitis and mild portal fibrosis without evidence of cirrhosis (Figure 1). AIH-PBC overlap syndrome was diagnosed and a combined therapy of UDCA (13-15 mg/kg daily) and budesonide (6 mg/d) was initiated. Two weeks later, her transaminases decreased by 50\% and azathioprine (100 mg/d) was administered. After 3 mo of combined therapy, all serum liver tests were normal and budesonide was tapered to 3 mg/d. At the last follow-up visit in August 2007, the patient reported an improved general condition, and fatigue and pruritus disappeared.

**AUTOIMMUNE CHOLANGITIS (AIC)**

**AIC-AIH OVERLAP SYNDROME**

AIC shares many features with PBC and is therefore also called AMA-negative PBC. Like PBC, it is characterized by a female preponderance, a cholestatic serum enzyme pattern and florid bile duct lesions on histology and it slowly progresses to fibrosis and cirrhosis of the liver if left untreated\textsuperscript{[39]}. Patients with AIC are AMA negative and often present with serum ANA and/or ASMA. Several studies support the view that AIC and PBC are variants of one single disease only differing in serum autoantibody pattern\textsuperscript{[36-38]}. Twenty-two of 30 patients...
with AIC (AMA-negative PBC), but none of the 316 controls, were positive in a new AMA-M2 recombinant assay which detected autoantibodies directed against human E2 members of the 2-oxo acid dehydrogenase enzyme complex[36]. In addition, immunohistochemical studies showed that PDC-E2 immunoreactivity was not only in patients with PBC, but also in 7 of 9 patients with AIC[37]. Treatment response to UDCA (13-15 mg/kg daily) and outcome of liver transplantation in end-stage disease were also similar in patients with AIC and those with PBC[39,40]. Thus, these data indicate that a majority of AIC patients (when defined as AMA-negative PBC) suffer from “true” PBC.

Concomitant features of AIH and AIC have been reported in single cases. An AMA-negative woman presented with features of an AIH-AIC overlap syndrome based on the presence of hepatitis and cholestatic biochemical changes and interface hepatitis as well as bile duct lesions on histology. In analogy to the therapy of AIH-PBC overlap syndrome, this patient responded to a combined treatment with UDCA and immunosuppressors[41].

**AIH-PSC OVERLAP SYNDROME**

While AIH-PBC overlap syndrome is predominantly found among adults, AIH-PSC overlap syndromes have mainly been described in children, adolescents and young adults[42-44]. Use of the modified AIH score led to the diagnosis of an overlap syndrome in 8% of 113 PSC patients and 1.4% of 211 PSC patients, respectively, when evaluated retrospectively[45,46]. However, diagnostic criteria are not defined for AIH-PSC overlap syndrome which makes comparability of these studies difficult. In a recently published prospective study, 41 consecutive patients who were diagnosed with PSC were evaluated for an AIH-PSC overlap syndrome[47]. The diagnosis of AIH-PSC overlap syndrome was established when the following criteria were met: (1) revised AIH score > 15; (2) ANA or ASMA antibodies present in a titre of at least 1:40; and (3) liver histology with piecemeal necrosis, lymphocyte rosetting, moderate or severe periporal or periseptal inflammation[47]. Of interest, the survival probability of the patients with AIH-PSC overlap syndrome was better than those with classical PSC as assessed by the Mayo score, a prognostic index.

The largest case series of AIH-PSC overlap syndromes in children and adolescents was published by colleagues from the Kings’ College in London[48]. In this prospective study, a group of 55 children was followed up for 16 years who showed clinical, biochemical, and histological signs of AIH. In 17 of the 55 children, cholangiographic findings were typical of sclerosing cholangitis, whereas other signs and symptoms were characteristic of AIH. Therefore, the term “autoimmune sclerosing cholangitis” (ASC) was proposed for this AIH-PSC overlap syndrome. Patients with ASC more commonly suffered from inflammatory bowel disease and more often were positive for ANCA in serum than those with AIH. Serum transaminases tended to be higher in AIH, but serum alkaline phosphatase although mostly elevated in PSC was normal at several occasions in both diseases. Thus, AIH and ASC may belong to the same disease process and may overlap with PSC.

Increasing awareness for the AIH-PSC overlap syndrome has led to the observation that AIH and PSC may be sequential in their occurrence, and this has first been described in children[49]. More recently, a similar observation has been reported in a small case series of 6 adults (mean age 31 years; 4 male; 3 with ulcerative colitis) who developed biochemical and cholangiographic features of PSC after an average of 4.6 years of a diagnosis of AIH and became resistant to immunosuppressive therapy[8]. Thus, in patients with AIH who become cholestatic and/or resistant to immunosuppression, PSC should be considered and ruled out.

**Therapy**

Ursodeoxycholic acid (UDCA) is widely administered in PSC due to its beneficial effects on serum liver tests,
histological features, prognostic surrogate markers, and development of colonic dysplasia associated with accompanying ulcerative colitis, although long-term efficacy of UDCA still remains unproven[40-52]. UDCA at higher doses (> 20 mg/kg daily) may be superior to standard doses for patients with PSC[53] and has also been used in the treatment of AIH-PSC overlap syndrome[47,54]. UDCA has been used in combination with immunosuppressive drugs in AIH-PSC overlap syndrome, and the long-term course was considered favorable[43,47]. Thus, UDCA in combination with an immunosuppressive regimen may be an adequate medical treatment for most patients with AIH-PSC overlap syndrome although data from controlled trials are lacking. Liver transplantation should be considered in late-stage diseases.

REFERENCES

1. Czaja AJ. The variant forms of autoimmune hepatitis. Ann Intern Med 1996; 125: 588-598
2. Poupon R. Autoimmune overlapping syndromes. Clin Liver Dis 2003; 7: 865-878
3. Beuers U. Hepatic overlap syndromes. J Hepatol 2005; 42 Suppl: S93-S99
4. Ben-Ari Z, Czaja AJ. Autoimmune hepatitis and its variant syndromes. Gut 2001; 49: 589-594
5. Chazouilleres O, Wendum D, Serfati L, Montembault S, Rossomorud O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28: 296-301
6. Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: A sequential syndrome. Hepatology 2002; 36: 1393-1399
7. Burak KW, Urbanski SJ, Swain MG. A case of coexisting primary biliary cirrhosis and primary sclerosing cholangitis: a new overlap of autoimmune liver diseases. Dig Dis Sci 2001; 46: 2043-2047
8. Pawlotsky JM, Ben Yahia M, Andre C, Voisin MC, Intrator L, Roudot-Thoraval F, Deforges I, Duvoux C, Zafrani ES, Duval J. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994; 19: 841-848
9. Lunel F, Arib A, Cauch-Dudek K, Wanless IR, Lindor KD, Jorgensen R, Dickson ER. Epidemiology and natural history of primary biliary cirrhosis and autoimmune hepatitis. Clin Liver Dis 2005; 21: 115-133
10. Colombo LA, Alvarez F, Cote J, Huet PM. Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis? Gastroenterology 1994; 107: 1839-1843
11. Poupon R, Chazouilleres O, Corpechot C, Chretien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006; 44: 85-90
12. Silveira MG, Talwalkar JA, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol 2007; 102: 1244-1250
13. Joshi S, Cauch-Dudek K, Wanles IR, Lindor KD, Jorgensen R, Batts K, Heathcote EJ. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 2002; 35: 409-413
14. Chazouilleres O, Wendum D, Serfati L, Rossomorud O, Poupon R. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol 2006; 44: 400-406
15. Wiegand J, Schuler A, Kanzler S, Lohe AW, [Presence of SLA/LP autoantibodies in patients with primary biliary cirrhosis as a marker for secondary autoimmune hepatitis (overlap syndrome)] Dtsch Med Wochenschr 2001; 126: 450-456
16. Miyakawa H, Tanaka A, Kikuchi K, Matsushita M, Okuno T, Seto Y, Okanoue T, Takino T. Chronic active hepatitis with histological features of primary biliary cirrhosis. Dig Dis Sci 1987; 32: 779-779
Kitazawa E, Kawaguchi N, Fujikawa H, Gershwin ME. Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens. *Hepatology* 2001; 34: 243-248

Tsuneyama K, Van De Water J, Van Thiel D, Coppel R, Ruebner B, Nakanuma Y, Dickson ER, Gershwin ME. Abnormal expression of PDC-E2 on the apical surface of biliary epithelial cells in patients with antimitochondrial antibody-negative primary biliary cirrhosis. *Hepatology* 1995; 22: 1440-1446

Ikuno N, Sealey M, Davies JM, Whittingham SF, Omagari K, Mackay IR, Rowley MJ. A comparative study of antibody expressions in primary biliary cirrhosis and autoimmune cholangitis using phage display. *Hepatology* 2001; 34: 478-486

Kim WR, Poterucha JJ, Jorgensen RA, Batts KP, Homburger HA, Dickson ER, Krom RA, Wiesner RH, Lindor KD. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. *Hepatology* 1997; 26: 22-26

Lacerda MA, Ludwig J, Dickson ER, Jorgensen RA, Lindor KD. Antimitochondrial antibody-negative primary biliary cirrhosis. *Am J Gastroenterol* 1995; 90: 247-249

Li CP, Tong MJ, Hwang SJ, Luo JC, Tsay SH, Chang FY, Lee SD. Autoimmune cholangitis with features of autoimmune hepatitis: successful treatment with immunosuppressive agents and ursodeoxycholic acid. *J Gastroenterol Hepatol* 2000; 15: 95-98

McNair AN, Moloney M, Portmann BC, Williams R, McFarlane IG. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. *Am J Gastroenterol* 1998; 93: 777-784

van Buuren HR, van Hoogstraten HJE, Terkivatan T, Schalm SW, Vleggaar FP. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. *J Hepatol* 2000; 33: 543-548

Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, Mieli-Vergani G. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. *Hepatology* 2001; 33: 544-553

Kaya M, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. *J Hepatol* 2000; 33: 537-542

van Buuren HR, van Hoogstraten HJE, Terkivatan T, Schalm SW, Vleggaar FP. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. *J Hepatol* 2000; 33: 543-548

Floreani A, Rizzotto ER, Ferrara F, Carderi I, Caroli D, Blasone L, Baldo V. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. *Am J Gastroenterol* 2005; 100: 1516-1522

Rust C, Beuers U. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. *Clin Rev Allergy Immunol* 2005; 28: 135-145

Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, Weinzierl M, Pape GR, Sauерbruch T, Paumgartner G. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. *Hepatology* 1992; 16: 707-714

Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann WJ, Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. *J Hepatol* 1994; 20: 57-64

Lindor KD. Ursodiol for primary sclerosing cholangitis. *Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med* 1997; 336: 691-695

Mitchell SA, Bansal DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. *Gastroenterology* 2001; 121: 900-907

Cullen SN, Rust C, Flemming K, Edwards C, Beuers U, Chapman RW. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. *J Hepatol* 2008; 48: 792-800

S- Editor Li DL  L- Editor Ma JY  E- Editor Yin DH